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GyraseA (GyrA) subunit of DNA gyrase from myco-
bacteria has certain characteristics distinct from that 
of E. coli. Polyclonal antibodies produced against M. 
tuberculosis GyrA recognized GyrA from different 
slow and fast growing mycobacterial species and also 
from several Gram-positive bacteria. However, these 
antibodies did not cross-react with E. coli GyrA and 
the enzyme from other Gram-negative bacteria. The 
results from the present study together with multiple 
alignment, pairwise comparison and biochemical 
properties support the idea of the occurrence of two 
subclasses of gyrases in the bacterial kingdom, empha-
sizing the importance of the enzyme as a molecular 
target for the development of novel therapeutics. 
DNA gyrase is unique amongst all known topoiso-
merases, as it is the only enzyme capable of introducing 
negative supercoils into DNA1–3. The enzyme is found 
only in bacteria and is essential for cell survival, since 
negative supercoiling of DNA is a prerequisite during 
replication, transcription and other DNA transaction 
processes2. DNA gyrase has been extensively studied 
from E. coli with respect to structure–f nction, biochem-
istry, oligomeric status and mechanistics of the supercoil-
ing reaction4–10. The E. coli enzyme is a heterotetramer, 
and consists of two subunits each of gyraseA (GyrA) and 
gyraseB (GyrB) encoded by gyrA and gyrB genes, res-
pectively5. GyrA is thought to be principally concerned 
with the breakage and reunion of DNA6, while GyrB 
subunit is the site of ATP hydrolysis11. The enzyme is the 
target of two major groups of antibacterial agents, the 
quinolones and coumarins. Since gyrase is a proven drug 
target, there has been considerable interest to study  
gyrase from different bacteria. As a consequence, gyrase 
genes have been characterized from Klebsiella pneumo-
niae12, Pseudomonas aerogenosa13, Mycoplasma pneu-
moniae14, Staphylococcus aureus15, Bacillus subtilis16, 
Streptomyces coelicolor17, Mycobacterium tuberculo-
sis18,19, M. smegmatis20, M. leprae21 and many others. In 
most of these cases, studies have been confined to eluc-
dating the mechanism of drug resistance, by identifying 
mutations in the gyrase genes. 
 The genus mycobacterium comprises more than fifty 
species and about twenty of them are of medical impor-
tance. Besides the most important mycobacterial patho-
gens such as M. tuberculosis and M. leprae, the 
respective causative agents of tuberculosis and leprosy, 
other mycobacteria such as M. avium, M. kansasii, M. 
chelonae and M. fortuitum can cause opportunistic infe-
tions in immunocompromised hosts. In order to address 
the role of gyrase in important processes in mycobacteria, 
for biochemical characterization nd to develop it as a 
suitable drug target, we have cloned gyrB and gyrA from 
M. smegmatis20 and M. tuberculosis18. These studies are  
important considering the worldwide reemergence of 
mycobacterial infections and the evolution of multidrug 
resistant (MDR) strains of M. tuberculosis22. 
 In this article, we describe the over-expr ssion of 
GyrA from M. tuberculosis, generation of polyclonal 
ant bodies and their utility in assessing the cross-
reactivity of GyrA subunits from various bacteria. The 
l k f immunological cross-reactivity between Gram-
positive and Gram-negative bacteria, along with sequence 
analysis of gyrase genes and other observations form the 
basis for us to suggest the existence of two subclasses of 
DNA gyrases. 
 
Materials and methods 
Bacterial strains, plasmids and materials 
M. smegmatis SN2 (Msg) and E. coli DH10b (Eco) were 
laboratory strains. M. tuberculosis H37Rv (Mtb) was 
obtained from National Tuberculosis Institute, Bangalore, 
India. M. avium, M. bovis, M. kansasii, M. fortuitim, M. 
gilvum, M. phlei and M. voccae were provided by Dr 
V. M. Katoch, Central JALMA Institute for Leprosy, Agra, 
India. M. leprae (Mlp) cell lysate was a kind gift from  
Dr P. J. Brennan, Colorado State University, Colorado, 
USA. Other Gram-positive bacteria, viz. S. coelicolor 
(Sco), B. subtilis (Bsu) and S. aureus (Sau) and Gram-
negative bacteria, viz. P. aerogenosa (Pae), K. pneumo-
niae (Kpn), and Salmonella typhimurium were obtained 
from the Institute of Microbial Technology, Chandigarh, 
India. Differnt mycobacteria were grown in modified  
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Youmans and Karlson’s medium23 with 0.2% Tween-80 
at 37°C. All other bacteria were grown according to the 
provider’s specifications. Restriction endonucleases and 
modifying enzymes were from Boehringer Mannheim, 
Amersham Pharmacia Biotech and New England Biolabs 
and used according to manufacturers’ specifications. All 
other reagents were purchased from Sigma. pET20b +
plasmid was obtained from Novagen. 
Preparation of cell-free extracts from bacterial strains
The cells were harvested at mid log phase by centrifuga-
tion at 6000 rpm for 20 min at 4°C and resuspended in 
sonication buffer (20 mM Tris pH 8.0, 1 mM EDTA, 
10% glycerol, 5 mM b-mercaptoethanol, 1 mM phenyl 
methyl sulphonyl fluoride (PMSF), 1 mM benzamidine 
HCl and 1% Triton X-100). The cells were lysed by soni-
cation (Virtis 475 Sonicator) and cell-free extracts were 
collected by centrifugation at 12,000 rpm for 30 min at 
4°C. Protein was estimated by the method of Bradford24. 
Hyper expression of GyrA and generatio  of 
polyclonal antibodies 
A 257 bp fragment from the 5¢ end of gyrA ORF was amp-
lified by PCR from the genomic clone pMN652 (ref. 18) 
using a 5¢ primer with a NdeI site providing the ATG start 
codon (5¢ TGAATTCATATGACTGATACGACG 3¢) and 
the pTZ19U reverse primer (5¢ CAGGAAACAGCTAT-
GAC 3¢) as the 3¢ primer. The PCR product was digested 
with NdeI and HindIII and cloned into NdeI/HindIII  
digested pET20b + to obtain pMK16. The cloned DNA 
fragment was sequenced to confirm the absenc of any 
mutations. The remaining part of the gyrA gene, a 2.6 kb 
NcoI fragment from a genomic clone pMN6R18, was 
cloned at the NcoI site in pMK16 (Figure 1 a) to obtain 
pMK17. 
  pMK17 was transformed into the E. coli strain BL21 
(DE3) pLysS and cells induced with IPTG (300 mM) for 
three hours. Cells were collected by centrifugation, re-
suspended in sonication buffer and lysed by sonication. 
The cell lysate was centrifuged at 12,000 rpm to obtain 
the pellet which contained the GyrA protein in inclusion 
bodies. The pellet was washed thrice in 10 mM phos-
phate buffer (pH 7.2) with 0.8% NaCl, and 0.1% Triton 
X-100 and subsequently three more times with the same 
buffer without detergent. The protein band corresponding 
to GyrA was purified by electroelution. Recombinant E. 
coli GyrA was purified from DH10b cells harbouring 
pPH3 plasmid as described by Maxwell and Howells25. 
 Antibodies were raised against purified Mtb GyrA  
protein in rabbits as described26. The antibody titer  
was determined using Enzyme Linked Immunosorbent  
– +  – +
96
66
42
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1     2 3    4                   
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Figure 1. a, Cloning strategy for M. tuberculosis gyrA gene in pET-20b +. The two-step cloning procedure involving PCR is depicte . Short 
arrows indicate the primers used in PCR with the forward primer carrying an NdeI site. The relevant restriction sites are shown; b, SDS-
polyacrylamide gel electrophoresis of E. coli BL21 (DE3)/pLysS cell lysates harbouring pET-20b + without induction (lane 1) or induction with 
IPTG (lane 2). E. coli cells harbouring plasmid pMK17 uninduced (lane 3) and induced with IPTG (lane 4). The size of the protein 
molecular weight markers is indicate . 
b a 
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Assay (ELISA) by coating 200 ng of MtbGyrA protein as 
described earlier26. 
Immunoblotting techniques 
SDS-PAGE was performed using 8% polyacrylamide 
separating gels27. Proteins from the gel were transferred 
to PVDF membrane and probed with respective anti-
bodies as described earlier26. Bound antibodies were  
detected by enhanced chemiluminiscence (Amersham 
ECL Plus) according to the manufacturer’s instructions. 
Sequence analysis 
UWGCG software was used for sequence analysis at the 
Distributed Information Centre, Indian Institute of Sci-
ence, Bangalore, India. The pairwise amino acid sequence 
comparison was performed using GAP and the phylo-
genetic tree was constructed using PILE UP. MACAW 
program28 was used for the multiple alignment of diffe-
rent GyrA proteins. 
Results and iscussion 
The cloning strategy for GyrA is depicted in Figure 1a. 
The strategy involved PCR amplification and cloning of 
the amino terminal small region and then direct in-frame 
insertion of a genomic fragment containing the rest of the 
gene. The full-length reconstructed gene is under the  
control of the Ø10 promoter of T7 bacteriophage in 
pET20b +. E. coli BL21 (DE3) pLysS cells harbouring 
pMK17 plasmid when induced with IPTG, expressed 
large amounts of protein (Figure 1 b), and the size of the 
over-expressed protein (92.5 kDa) corresponded to the 
expected molecular mass deduced from the primary  
sequence. Most of the over-expressed protein was local-
ized to inclusion bodies but this facilitated its purification 
by electroelution. 
 In order to assess the immunological relatedness  
between GyrA from different bacteria, polyclonal anti-
bodies were raised against mycobacterial GyrA subunit. 
The antibodies generated were of high titer, based on 
quanti ative ELISA using M. tuberculosis GyrA. Cross-
reactivity of GyrA polyclonal antibodies with E. coli 
GyrA was evaluated and for this purpose E. coli GyrA 
was over-expressed and purified as described25. M. tuber-
culosis GyrA is 6 kDa smaller than the 98 kDa E. coli 
GyrA (Figure 2 a). In spite of 46.6% identity (59.8% 
similarity) at the amino acid level between E. coli and  
M. tuberculosis GyrA subunits, the antibodies did not 
show cross-reactivity with the E. coli enzyme (Figure 
2 b, lane 1). Similar results were obtained even at a lower 
dilution of the antiserum. The polyclonal antibodies 
raised in mouse against M. smegmatis GyrA also did not 
cross-react with E. coli protein suggesting that it is not a 
limitation of the experimental protocol (data not shown). 
We have extended these studies furth r by employing 
two different monoclonal antibodies generated against  
E. coli GyrA subunit recognizing different regions on E. 
coli GyrA29. These mAbs also did not cross-react with  
M. tuberculosis GyrA. It should be noted that GyrA from 
E. coli and M. tuberculosis share several conserved  
motifs. The absence of cross-reactivity between GyrA 
from two different species of bacteria though surprising, 
has also been reported earlier. E. coli GyrA polyclonal 
antibodies did not cross-react with the GyrA subunit of 
B. subtilis30. 
 The cross-reactivity of antibodies raised against Mtb 
GyrA with other Gram-positive and Gram-negative bac-
teria was tested. Significant cross-reactivity of Mtb GyrA 
antiserum with cell extracts from Gram-positive bacteria 
was observed (Figure 3 a). The size of the immunoreac-
tive protein in these cell extracts corresponded to the  
expected molecular mass of GyrA, except in the case of 
S. aureus. The abnormal faster mobility in the latter case 
could be due to rapid degradation of the protein, possibly 
an intrinsic feature of that polypeptide. In contrast to the 
results with Gram-positive bacteria, hardly any cross-
reactivity with M. tuberculosis GyrA immune serum was 
observed with cell-free extracts from Gram-negative bac-
t ria (Figure 3 b). 
 The cross-reactivity profile of anti Mtb GyrA anti-
bodies with various bacterial species indicates that the 
antigenecity of GyrA is uniquely conserved in Gram-
positive bacteria. These results correlate well with the 
extent of similarity shared by different GyrA polype-
tides (Table 1), which show a higher degree of sequence  
Figure 2. Specificity of Mtb : GyrA polyclonal antibody. SDS-
polyacrylamide gel electrophoresis (a) and Western blot analysis (b) of 
1 mg each of purified E. coli GyrA (lane 1) and M. tuberculosis GyrA 
(lane 2). Antiserum to MtbGyrA was used at a 1 : 10000 dilution. Sizes 
of molecular mass markers (lane 3) are indicated on the right. 
 
b a 
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similarity amongst Gram-positive bacteria than Gram-
negative bacteria. The immunological difference between 
different GyrA subunits also seems to correlate well with 
their pattern in the unrooted phylogenetic tree (Figure 4). 
 The polyclonal antiserum was tested for cross-rea ti-
vity with different mycobacterial species belonging to 
fast and slow growing groups and the results are pre-
sented in Figure 5 a and b, respectively. Mtb GyA anti-
serum cross-reacted well with both fast growing and slow 
growing mycobacteria, indicating that GyrA is very simi-
lar among different mycobacterial species with respect to 
size and immunogenicity of the protein. The antibodies 
also cross-reacted with M. leprae GyrA. It should be 
noted that in M. leprae, the size of the mature GyrA 
polypeptide is 853 amino acids which is initially synthe-
sized as a precursor containing a 420 amino acid intein21. 
The intein-containing precursor could not be detected by 
Western blot analysis, indicating the rapid processing f 
precursor protein to form the mature 95 kDa form. 
 An alignment of the amino acid sequences of the  
GyrA subunits is shown in Figure 6. The N-terminus of 
GyrA from different Gram-positive and Gram-negative 
bacteria is largely conserved. In E. coliGyrA, tyrosine-
122 is responsible for transient DNA scission via a 
DNA–phosphotyrosine intermediate31 and in the various 
protein sequences surrounding the active site, tyrosine 
(AAMRYTE) is highly conserved. In contrast, the car-
boxy terminal domain (CTD) of GyrA proteins is  
divergent. The differences in CTD, a region which is res-
ponsible for DNA binding, could imply subtle differences 
in DNA-binding properties of the enzyme. Furthermore, 
a stretch of 34 amino acids, located towards the middle  
of the protein in Gram-negative bacteria is absent in all 
GyrAs from Gram-positive bacteria and the importance 
of h s region is yet to be elucidated. 
 A similar comparison of GyrB proteins in various bac-
teria also shows regions of similarity towards the amino 
terminal. Two important residues, Glu-42 and His-38, 
implicated in ATPase activity of GyrB of E. coli32, are 
highly conserved in all the GyrB sequences. We have 
earlier noted a major difference in the primary amino 
acid sequences of GyrB of Gram-positive and Gram-
negative bacteria33. A contiguous stretch of 165 amino 
acids is missing from Gram-positive bacteria and myco-
plasma, which is present in E. coli GyrB and other Gram-
negative bacteria. Our studies have indicated that this 
region is essential for the DNA-binding ability of the  
active gyrase tetramer, and deletion of this stretch  
impairs activity of E. coli gyrase both in vivo and in  
vitro34. These results suggest the presence of an alternate 
DNA binding region in GyrB of Gram-positive bacteria. 
 The differences in the properties of DNA gyrase from 
two major eubacterial groups are further apparent on the 
basis of studies using the quinolone class of drugs. Data 
from several laboratories indicate that quinolones are 
targetted primarily to DNA gyrase in Gram- egative bac-
teria; topoisomerase IV serves as a secondary target35,36. 
In contrast, topoisomerase IV appears to be the primary  
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Figure 3. Immunological cross-reactivity of DNA gyrases from vari-
ous Gram-positive (a) and Gram-negative  (b) bacteria. 30 mg of pro-
tein from different bacterial cell lysates was subjected to 8% SDS-
PAGE and blotted onto PVDF membranes. The blots were probed with 
1 : 10000 (a) and 1 : 5000 (b) dilution of anti-Mtb GyrA antiserum and 
processed as described in the materials and methods section. 
 
b 
a 
Figure 4. Evolutionary relationship among GyrA subunits. Unrooted 
phylogenetic trees produced from the alignment of GyrA subunits 
using Phylip. 
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 cytotoxic target for most members of this drug family in 
Gram-positive bacteria37. 
 Despite the highly conserved region near oriC in the 
genome of eubacteria, there is a difference in gyrB and 
gyrA gene arrangements in Gram-positive and Gram-
negative bacteria. In all the characterized Gram-positive 
bacteria, i.e. S aureus15, B. subtilis16, S. sphaeroides38, 
M. tuberculosis18, M. smegmatis20, M. leprae39 and halo-
phylic archaebacteria40, gyrA and gyrB genes are con-
tiguous or found in close proximity to each other. In most 
of the Gram-negative bacteria, i.e. E  coli41, P. aero-
genosa42 and K. pneumoniae12 however, the genes are 
found far apart on the chromosome. We have shown ear-
lier that gene structure, transcriptional organization and 
regulation of the gyr operon in mycobacteria are different 
from that of E. coli43. From these results, it appe rs that 
in spite of substantial similarities at the amino acid level, 
there are significant differences in the structure and reg-
lation of gyrase enzyme in different bacteria. 
 Taken together, these results lead us to propose the 
existence of two subclasses of gyrases represented in 
Gram-positive and Gram-negative bacteria. It is clear that 
the overall reaction cycle catalysed by the members of 
the either class is similar, as motifs important for cata-
lysis are conserved in all the gyrase sequences character-
ized so far. The differences observed in the gene structure 
and protein sequence could have evolved in a species 
or genera-specific manner. These differences could be 
involved in subtly influencing catalytic properties and the 
modulation of enzyme function. A detailed comparative 
study of the biochemical properties of gyrase from these 
two different classes would be necessary to understand 
the functional basis for the differences in order to exploit  
Table 1. Pairwise comparison of GyrA subunits (% similarity/% identity)* from different bacteria                     
 Mtb Mlp Msg Sco Bsu Sau Pae Kpn Eco 
                    
Mtb 100      
100     
92.7 
90.1 
93.7 
89.7 
75.4 
65.5 
60.6 
49.5 
59.4 
47.6 
58.7 
46.5 
59.7 
46.9 
59.8 
46.6 
Mlp 92.7 
90.1 
100     
100     
91.2 
86.9 
72.9 
63.5 
60.8 
49.8 
58.4 
46.4 
58.8 
45.1 
58.7 
45.8 
58.8 
46.2 
Msg 93.7 
89.7 
91.2 
86.9 
100     
100     
75.4 
66.1 
61.1 
50.2 
58.3 
47.4 
58.4 
46.1 
60.9 
47.2 
60.4 
47.1 
Sco 75.4 
65.5 
72.9 
63.5 
75.4 
66.1 
100    
100    
60.4 
49.0 
59.6 
48.7 
58.9 
47.3 
59.6 
48.2 
59.6 
47.7 
Bsu 60.6 
49.5 
60.8 
49.8 
61.1 
50.2 
60.4 
49.0 
100     
100     
74.9 
64.7 
65.5 
53.4 
65.6 
53.7 
66.2 
53.9 
Sau 59.4 
47.6 
58.4 
46.4 
58.3 
47.4 
59.6 
48.7 
74.9 
64.7 
100     
100     
61.8 
48.6 
63.2 
50.8 
64.3 
51.6 
Pae 58.7 
46.5 
56.8 
45.1 
58.4 
46.1 
58.9 
47.3 
65.5 
53.4 
61.8 
48.6 
100     
100     
76.7 
66.5 
77.7 
67.1 
Kpn 59.7 
46.9 
58.7 
45.8 
60.9 
47.2 
59.6 
48.2 
65.6 
53.7 
63.2 
50.8 
76.7 
66.5 
100     
100     
92.6 
89.4 
Eco 59.8 
46.6 
58.8 
46.2 
60.4 
47.1 
59.6 
47.7 
66.2 
53.9 
64.3 
51.6 
77.7 
67.1 
92.6 
89.4 
100     
100     
          
          
*In each cell, the top value is % similarity and the bottom value is % identity. 
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Figure 5. Immunological characterization of DNA GyrA from dif-
ferent mycobacteria species by Western blot analysis. 20 mg of fast 
growing (a) and slow growing (b) mycobacterial cell lysates was sub-
jected to SDS-PAGE and further analysed by immunoblotti g with 
1 : 20000 Mtb anti-GyrA antiserum. 
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the enzyme as a specific molecular target for the deve-
lopment of new drugs. 
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